MediciNova announces new research collaboration for MN-001 in Japan
Category: #health  By Mateen Dalal  Date: 2019-08-01
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

MediciNova announces new research collaboration for MN-001 in Japan
  • MediciNova will collaborate with the NCVC in Japan.
  • Research would evaluate the effects of MN-001 on lipid metabolism and metabolic syndrome.

MediciNova Inc., a California-based biopharmaceutical firm traded on JASDAQ of Tokyo Stock Exchange and NASDAQ Global Market, announced that the starting of a research collaboration with Japanese National Cerebral and Cardiovascular Disease Research Center (NCVC), Department of Molecular Innovation in Lipidology, Division of Lipid Metabolism, to assess the efficacies of MN-001, also known as tipelukast on metabolic syndrome and lipid metabolism.

The Chief Executive Officer and President at MediciNova, Inc., Yuichi Iwaki, Ph.D., M.D.  stated that tipelukast is a new orally administered product with various mechanisms, as well as its anti-inflammatory and anti-fibrosis effects have been studied in several animal model researches.

Iwaki further stated that tipelukast significantly reduced levels of serum triglyceride in a recent medical test that had patients with NAFLD and NASH with hypertriglyceridemia. MediciNova believes that partnering with Lipid Metabolism Research Group, NCVC can considerably raise the potential worth of MN-001.

The Head Researcher of the research collaboration, Dr. Masatsune Ogura from NCVC stated that the research center is thrilled to get the opportunity to study further the multiple mechanisms of MN-001, which have been showcased, and to further explore the mechanisms through which tipelukast triggers lipid metabolism changes. Researchers would also be considering the effect of tipelukast on metabolic diseases.

About MediciNova:

MediciNova is a biopharmaceutical firm that is established upon the development of new, small-molecule drug therapies for treating illnesses with unmet medical requirements with a commercial focus on U.S. healthcare market.

MediciNova’s present strategy is to focus its efforts on MN-166 (ibudilast) for addressing neurological disorders like degenerative cervical myelopathy, amyotrophic lateral sclerosis, progressive multiple sclerosis, glioblastoma and substance dependence (opioid dependence, methamphetamine dependence, alcohol use disorder) and MN-001 for fibrotic disorders like idiopathic pulmonary fibrosis and nonalcoholic steatohepatitis. MediciNova pipeline also contains MN-029 (denibulin) and MN-221 (bedoradrine).

Source Credit: https://investors.medicinova.com/news-releases/news-release-details/medicinova-announces-mn-001-research-collaboration-national

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

China unveils plans to reinforce stringent safety standards for EVs

China unveils plans to reinforce stringent safety standards for EVs

By Mateen Dalal

This news comes amid rising incidences of battery fires and breaks failures. China will require automakers to have a 24-hour emergency response system to address major accidents. China is planning to reinforce strict safety standards for electri...

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...